NetworkNewsBreaks – AVROBIO Inc. (NASDAQ: AVRO) Featured in Mizuho Securities Research Report
AVROBIO (NASDAQ: AVRO) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are raising our PT on AVRO from $28 to $35 following positive clinical data updates yesterday at WORLDSymposium 2020 where we also attended the company's analyst event. Clinical data in Fabry continues to support a potential best-in-class gene therapy, and transition from academic process to AVRO's proprietary platform could offer additional clinical benefits. Initial data in Cystinosis was also positive, further supporting AVRO's gene therapy platform. Multiple data updates are expected throughout 2020, along with potential regulatory updates,…







